Company / Financials
ALX ONCOLOGY HOLDINGS INC Financials
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2022 · -100.0% YoY
Net Income
-$123.5M
FY2022 · -541.7% YoY
Profit Margin
-
FY2022 · net income / revenue
ROE
-46.9%
FY2022 · return on equity
Total Assets
$306.5M
FY2022
Total Debt
$10.6M
0.04x debt/equity
Equity
$263.5M
FY2022
ROA
-40.3%
FY2022 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0-100.0% YoYNet Income HistoryProfit after all expenses and taxes-$123.5M-541.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$127.4M-564.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$29.0M+776.4% YoYR&D Expense HistoryResearch and development spending$98.4M+503.5% YoYInterest Expense HistoryCost of borrowing and debt obligations$238.0KIncome Tax HistoryTotal income tax expense$64.0K+88.2% YoYEPS (Basic) HistoryBasic earnings per share-$2.76EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.76+63.5% YoYShares Outstanding HistoryWeighted average diluted shares outstanding40.6M+1.9% YoY